Investors expect Luyan Pharma Co.,Ltd.'s limited growth rates to continue, contributing to its low P/E ratio. The recent medium-term earnings trends, worse than market expectations, also play a part. Investors believe the potential for earnings improvement doesn't justify a higher P/E ratio.
鷺燕醫葯股票討論區
暫無評論